The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review
- PMID: 40630797
- PMCID: PMC12237565
- DOI: 10.1155/carj/1682546
The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review
Abstract
Systemic sclerosis (SSc) is predominantly characterized by an array of cutaneous manifestations including Raynaud's phenomenon, calcinosis, telangiectasias, and skin fibrosis contributing toward substantial morbidity and diminished quality of life. The monumental impact of the disease regarding mortality is due to its pulmonary involvement known as SSc-associated interstitial lung disease (SSc-ILD). Currently, treatment is chiefly directed toward impeding disease progression with the mainstay treatment approaches involving the utilization of cyclophosphamide, mycophenolate mofetil, rituximab, and tocilizumab. Recently, a tyrosine kinase inhibitor, nintedanib, has been approved for the treatment of SSc-ILD and thus became the first medication to be fully licensed for SSc-ILD. A systematic review based on the Preferred Reporting Items of Systematic Review with Meta-analysis (PRISMA) was conducted after successful registration in PROSPERO to evaluate the efficacy and safety of nintedanib in SSc-ILD. We searched PubMed, Scopus, and CENTRAL up to the first of September 2023 utilizing the following keywords: ((Diffuse Parenchymal Lung Disease) OR (Diffuse Parenchymal Lung Diseases) OR (Interstitial Lung Disease) OR (Interstitial Lung Diseases) OR (Interstitial Pneumonia) OR (Interstitial Pneumonitis) OR (Pulmonary Fibrosis)) AND ((Systemic Scleroderma) OR (Systemic Scleroderma)) AND ((BIBF 1120) OR (BIBF-1120) OR (BIBF1120) OR (Nintedanib esylate) OR (Ofev) OR (Vargatef)). The clinical safety profile of nintedanib was deemed more favorable than other therapeutic regimens currently utilized, in addition to adequate clinical efficacy toward SSc-ILD.
Keywords: autoimmune lung disease; scleroderma; systemic sclerosis; tyrosine kinase inhibitor.
Copyright © 2025 Khaled S. Al Oweidat et al. Canadian Respiratory Journal published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2. Cochrane Database Syst Rev. 2018. PMID: 29297205 Free PMC article.
-
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.Clin Rev Allergy Immunol. 2023 Jun;64(3):239-261. doi: 10.1007/s12016-021-08891-0. Epub 2021 Sep 1. Clin Rev Allergy Immunol. 2023. PMID: 34468946 Free PMC article. Review.
-
Dynamics of interstitial lung disease following immunosuppressive treatment differ between antisynthetase syndrome and systemic sclerosis.Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251336896. doi: 10.1177/17534666251336896. Epub 2025 May 8. Ther Adv Respir Dis. 2025. PMID: 40337907 Free PMC article.
-
Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.Am J Respir Crit Care Med. 2024 Jan 15;209(2):137-152. doi: 10.1164/rccm.202306-1113ST. Am J Respir Crit Care Med. 2024. PMID: 37772985 Free PMC article.
-
Efficacy and safety of pharmacological treatments for autoimmune disease-associated interstitial lung disease: A systematic review and network meta-analysis.Semin Arthritis Rheum. 2024 Oct;68:152500. doi: 10.1016/j.semarthrit.2024.152500. Epub 2024 Jun 27. Semin Arthritis Rheum. 2024. PMID: 39002345
References
-
- Van Den Hoogen F., Khanna D., Fransen J., et al. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Annals of the Rheumatic Diseases . 2013;72(11):1747–1755. doi: 10.1136/annrheumdis-2013-204424. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical